Alternatives to GBCA: Are We There Yet?

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Topics in Magnetic Resonance Imaging (TMRI)

• Publication date

  2016-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/RMR.0000000000000096PMID 27367312
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents—current status

  2016influential reference
• Retrospective assessment of the utility of an iron‐based agent for contrast‐enhanced magnetic resonance venography in patients with endstage renal diseases

  2014influential reference
• Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer.

  2013cited by this paper
• Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.

  2013cited by this paper
• Abstract 107: Early Change in Ferumoxytol-Enhanced Magnetic Resonance Imaging Signal Suggests Unstable Human Cerebral Aneurysm. A Pilot Study

  2013cited by this paper
• Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: a human study using a multi-parametric cardiovascular magnetic resonance imaging approach.

  2013cited by this paper
• Manganese chloride tetrahydrate (CMC-001) enhanced liver MRI: evaluation of efficacy and safety in healthy volunteers

  2012cited by this paper
• Early Change in Ferumoxytol-Enhanced Magnetic Resonance Imaging Signal Suggests Unstable Human Cerebral Aneurysm: A Pilot Study

  2012cited by this paper
• Contrast-enhanced functional blood volume imaging (CE-fBVI): Enhanced sensitivity for brain activation in humans using the ultrasmall superparamagnetic iron oxide agent ferumoxytol

  2012cited by this paper
• Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application.

  2011cited by this paper
• Manganese-Based Oral Contrast Agent for Liver Magnetic Resonance Imaging: Evaluation of the Time Course and Dose Response of Liver Signal Intensity Enhancement

  2010cited by this paper
• High-resolution MR lymphography using ultrasmall superparamagnetic iron oxide (USPIO) in the evaluation of axillary lymph nodes in patients with early stage breast cancer: preliminary results

  2010cited by this paper
• Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement.

  2008cited by this paper
• MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study.

  2008cited by this paper
• Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer.

  2008cited by this paper
• THE POTENTIAL OF FERUMOXYTOL NANOPARTICLE MAGNETIC RESONANCE IMAGING, PERFUSION, AND ANGIOGRAPHY IN CENTRAL NERVOUS SYSTEM MALIGNANCY: A PILOT STUDY

  2007cited by this paper
• Abdominal-Pelvic MRI

  2007cited by this paper
• MR contrast agents for liver imaging: what, when, how.

  2006cited by this paper
• Clinical Management of Hepatic Malignancies: Ferucarbotran-Enhanced Magnetic Resonance Imaging Versus Contrast-Enhanced Spiral Computed Tomography

  2005cited by this paper
• Three‐dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: Comparison with superparamagnetic iron oxide‐enhanced MR imaging

  2004cited by this paper
• Decrease of Signal Intensity of Myometrium and Cervical Stroma After Ultrasmall Superparamagnetic Iron Oxide (USPIO) Particles Administration: An MR Finding With Potential Benefits in T Staging of Uterine Neoplasms

  2004influential reference
• Value of a blood pool contrast agent in MR venography of the lower extremities and pelvis: Preliminary results in 12 patients

  2003cited by this paper
• Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging

  2003cited by this paper
• MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage.

  2003cited by this paper
• Contrast Agents for Magnetic Resonance Imaging: Safety Update

  2003influential reference
• Pelvic lymph node visualization with MR imaging using local administration of ultra‐small superparamagnetic iron oxide contrast

  2002influential reference
• Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study.

  2002cited by this paper
• Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR) – results of a phase-III multicenter clinical trial

  2002cited by this paper
• Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement.

  2002cited by this paper
• Characterization of focal hepatic lesions with SPIO-enhanced MRI.

  2002cited by this paper
• Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes.

  2002cited by this paper
• MR imaging of intrahepatic cholangiocarcinoma: use of ferumoxides for lesion localization and extension.

  2001cited by this paper
• Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles

  2001cited by this paper
• Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A)

  2001cited by this paper
• Ferumoxide-enhanced MRI in patients with colorectal cancer and rising CEA: surgical correlation in early recurrence.

  2000cited by this paper
• Equilibrium-phase MR angiography of the aortoiliac and renal arteries using a blood pool contrast agent.

  2000cited by this paper
• Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis.

  2000cited by this paper
• Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma

  1999cited by this paper
• Improved delineation of human brain tumors on MR images using a long‐circulating, superparamagnetic iron oxide agent

  1999cited by this paper
• Pulmonary MR angiography with ultrasmall superparamagnetic iron oxide particles as a blood pool agent and a navigator echo for respiratory gating: pilot study.

  1999cited by this paper
• Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.

  1996cited by this paper
• Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 mumol/kg body weight in detecting focal liver tumors: results of a phase III trial using an infusion technique.

  1996cited by this paper
• Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck.

  1994cited by this paper
• Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions. Initial findings.

  1994cited by this paper
• Focal liver lesions: MR imaging with Mn-DPDP--initial clinical results in 40 patients.

  1992cited by this paper
• Hepatobiliary MR imaging: first human experience with MnDPDP.

  1991cited by this paper
• Magnetic resonance imaging contrast agents: theory and application to the central nervous system.

  1990cited by this paper

• Toward deep learning replacement of gadolinium in neuro-oncology: A review of contrast-enhanced synthetic MRI

  2023cites this paper
• Low-Molecular-Weight Fe(III) Complexes for MRI Contrast Agents

  2022cites this paper
• A generic deep learning model for reduced gadolinium dose in contrast‐enhanced brain MRI

  2021cites this paper
• Application of contrast-enhanced magnetic resonance imaging in the assessment of blood-cerebrospinal fluid barrier integrity.

  2021influential citation
• Two in One: Use of Divalent Manganese Ions as Both Cross-Linking and MRI Contrast Agent for Intrathecal Injection of Hydrogel-Embedded Stem Cells

  2021cites this paper
• Fe(deferasirox)2: An Iron(III)-Based Magnetic Resonance Imaging T1 Contrast Agent Endowed with Remarkable Molecular and Functional Characteristics.

  2021cites this paper
• Physicochemical and Pharmacokinetic Profiles of Gadopiclenol

  2019cites this paper
• Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care

  2018cites this paper
• Gadolinium-Based Contrast Agents: Associated Adverse Reactions.

  2017cites this paper
• Gadolinium Retention and Toxicity-An Update.

  2017cites this paper
• Preventing Allergic Reactions to Gadolinium-Based Contrast Agents

  2016cites this paper